ClinicalTrials.gg
RecruitingNCT07654829Updated Sep 17, 2026

Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

A Phase 4 interventional study of KVD900 600 mg in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..

Started
2026
the only one that year
Phase 4
Only one
of the 12
Registered
12th of 12
by date

Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2026, is the only one in phase 4, and was the 12th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • KVD900
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥12 years of age at time of Screening
  2. Confirmed diagnosis of HAE Type I or II based on patient report
  3. Patient has a qualifying procedure that is scheduled or planned to be scheduled to occur within 8 weeks of Screening
  4. Patient has access to a commercial available on-demand treatment for HAE
  5. Female patients of , including post-menarchal adolescents, must meet requirements per Section 11.3. (Note: male patients do not require contraception)
  6. Patients must be able to swallow trial tablets whole
  7. Patients, as assessed by the Investigator, must be able to appropriately receive and store IMP, and be able to read, understand, and complete the questionnaire
  8. Investigator believes that the patient is willing and able to adhere to all protocol requirements through the duration of the trial
  9. Patient provides or assent (when applicable). A parent or legally authorized representative (LAR) must also provide signed informed consent when required

Exclusion criteria

Exclusion Criteria:

  1. A history of poor response to bradykinin receptor 2 blocker, C1-INH therapy, or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator
  2. Use of angiotensin-converting enzyme (ACE) inhibitors within 7 days prior to the Screening Visit
  3. Any estrogen-containing medications with systemic absorption (such as oral including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit
  4. Patients who are taking strong cytochrome P450 (CYP)3A4 inhibitors or inducers or moderate inducers within 2 weeks of the procedure
  5. Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial
  6. History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator
  7. Known to sebetralstat or to any of the
  8. Participation in any gene therapy treatment or trial for HAE
  9. Any pregnant or breastfeeding patient
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    KVD900 600 mg

    Drug: KVD900 600 mg

Interventions

06

What researchers measure

Primary outcomes

  1. The number and proportion of STPs that did not result in an HAE attack within 24 hours after the start of the procedure will be summarized.

    Time frame: 24 hours following the start of the procedure

07

Study locations

1 of 1 sites recruiting
  • KalVista Investigative Site
    Colorado Springs, Colorado 80907, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing but only after deidentification of individual patient data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Nov 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartActual
Aug 17, 2026
Primary completionEst.
Nov 29, 2027
CompletionEst.
Dec 6, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07654829
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Aug 17, 2026
Primary completion
Nov 29, 2027 (estimated)
Completion
Dec 6, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

KalVista Pharmaceuticals
Contact
clinicalstudies@kalvista.com
1 (857) 999-0075
Study Director
study director · KalVista Pharmaceuticals, Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebetralstat

Start the discussion